Enarodustat for anemia in chronic kidney disease (not on dialysis)
Treatments studied
Part of Blood & lymphatic, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests enarodustat, a pill for anemia, in people with chronic kidney disease who are not on dialysis. It aims to see if it can safely raise hemoglobin levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Aged 18 to 75 years old
- Weigh between 99 and 220 pounds (45 to 100 kg)
- Have chronic kidney disease stages 2 to 5 and not on dialysis
- Have anemia (low red blood cells) linked to kidney disease, with specific hemoglobin levels
- Have enough iron in your body (ferritin over 100 μg/L or transferrin saturation over 20%)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a daily pill that helps people with chronic kidney disease and anemia make more red blood cells, which may reduce the need for other anemia treatments. It is for patients who are not on dialysis and do not plan to start dialysis or have a kidney transplant within the next six months.
This trial tests a new oral medicine (AND017) for people on dialysis who have anemia (low red blood cells). It may help reduce the need for injections of standard anemia medicines.
This trial tests whether starting enarodustat (a pill) at different doses can raise red blood cell levels and treat anemia in people with moderate-to-severe chronic kidney disease who are not yet on dialysis.
This trial tests an oral medication (AND017) for anemia caused by chronic kidney disease. It aims to improve red blood cell levels without needing dialysis or current anemia treatments.
This study tests two medicines (daprodustat and epoetin alfa) to see which one works better for treating low red blood cell counts (anemia) in people with chronic kidney disease who are not on dialysis yet. Both medicines aim to increase hemoglobin and reduce fatigue.
This trial tests a new drug called enarodustat combined with an existing immune-suppressing medicine (CsA) to treat aplastic anemia—a rare blood disorder where your bone marrow doesn't make enough blood cells. The goal is to help your body produce more red blood cells without needing a bone marrow transplant.
Hear when a new Chronic Kidney Disease Associated Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.